Antigen Presentation Pathway
AACR 2021 Poster
First-in-class inhibitors of ERAP1 have the potential to be a transformative immunotherapy in oncology.
Please leave this field empty.
* I consent to giving the above information to Grey Wolf Therapeutics. I am aware my details will be saved for contact and marketing purposes.
Find out more.